Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Nichi-Iko Pharmaceutical Co., Ltd.    4541   JP3687200000

NICHI-IKO PHARMACEUTICAL CO., LTD.

(4541)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Japan's Nichi-Iko jumps on hopes for steroid sales boost to treat COVID-19

share with twitter share with LinkedIn share with facebook
06/17/2020 | 03:28am EDT

Shares in Japanese generic drug maker Nichi-Iko Pharmaceutical Co, whose products include steroid drug dexamethasone, jumped nearly 5% on Wednesday after trial results showed it helped reduce death rates of COVID-19 patients.

Researchers in Britain said on Tuesday dexamethasone, used to reduce inflammation in other diseases such as arthritis, cut death rates of the most severely ill COVID-19 patients by around a third, making it the first drug shown to be able to save the lives of people with the respiratory disease.

Peter Horby, an Oxford University professor co-leading the trial, known as the RECOVERY trial, said in a statement that the drug should become standard of care for patients sick enough to require oxygen treatment.

"Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide," he said

Nichi-Iko said it and Bristol-Myers Squibb unit Celgene both sell the drug in Japan.

Nichi-Iko, which sells the drug under the brand name Decadron, is aware of the British research but hasn't as yet seen a surge in demand, spokesman Taichi Kitao. The company is ready to proactively supply the drug as needed, he said.

Britain's health ministry said the drug had been approved for use in the state-run health service, export restrictions had been introduced and 200,000 courses of the treatment had been stockpiled.

Dexamethasone is currently on the U.S. Food and Drug Administration's list of drugs in shortage. Still several suppliers including one of the largest - Germany's Fresenius SE - say they have the drug on the hand.

Shares in Nichi-Iko climbed 4.7% on Wednesday, outperforming a 0.6% drop in the broader market <.N225>.

(Reporting by Rocky Swift; Writing by Miyoung Kim; Editing by Edwina Gibbs)

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA -0.79% 72.94 Delayed Quote.11.52%
FRESENIUS SE & CO. KGAA -0.99% 39.17 Delayed Quote.-21.18%
NICHI-IKO PHARMACEUTICAL CO., LTD. 1.99% 1284 End-of-day quote.-5.66%
share with twitter share with LinkedIn share with facebook
Latest news on NICHI-IKO PHARMACEUTICAL C
07/21NICHI IKO PHARMACEUTICAL : Japan approves dexamethasone as coronavirus treatment
RE
07/21NICHI IKO PHARMACEUTICAL : Japan approves dexamethasone as coronavirus treatment
RE
06/17Japan's Nichi-Iko jumps on hopes for steroid sales boost to treat COVID-19
RE
06/09NICHI IKO PHARMACEUTICAL : The University of Tokyo, RIKEN, Nichi-Iko and Daiichi..
AQ
06/01Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against S..
AQ
03/30NICHI-IKO PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
03/06NICHI IKO PHARMACEUTICAL : Ono Pharmaceutical Co - ONO and Nichi-Iko Enter into ..
AQ
2019NICHI-IKO PHARMACEUTICAL CO., LTD. : Ex-dividend day for interim dividend
FA
2019NICHI IKO PHARMACEUTICAL : Sagent Pharmaceuticals Announces FDA Acceptance of Om..
AQ
2019NICHI-IKO PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
More news
Financials
Sales 2021 198 B 1 849 M 1 849 M
Net income 2021 5 100 M 47,7 M 47,7 M
Net Debt 2021 84 056 M 786 M 786 M
P/E ratio 2021 15,5x
Yield 2021 2,34%
Capitalization 82 099 M 771 M 768 M
EV / Sales 2021 0,84x
EV / Sales 2022 0,78x
Nbr of Employees 1 954
Free-Float 80,7%
Chart NICHI-IKO PHARMACEUTICAL CO., LTD.
Duration : Period :
Nichi-Iko Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICHI-IKO PHARMACEUTICAL C
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 1 341,67 JPY
Last Close Price 1 284,00 JPY
Spread / Highest target 16,8%
Spread / Average Target 4,49%
Spread / Lowest Target -6,54%
EPS Revisions
Managers
NameTitle
Yuichi Tamura President & Representative Director
Naoyuki Okada Finance Manager
Toshinori Kongoji Director
Noboru Inasaka Director & Senior Managing Executive Officer
Kenji Akane Director, VP, Head-CSR, ESG & Business Creation
Sector and Competitors